Methicillin-Resistant Staphylococcus aureus Bloodstream Infections in Hospitalized Patients in Peru

Am J Trop Med Hyg. 2023 Sep 18;109(5):1118-1121. doi: 10.4269/ajtmh.23-0054. Print 2023 Nov 1.

Abstract

There is a knowledge gap in the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) causing bloodstream infections (BSIs) in Peru. Through a surveillance study in 13 hospitals of 10 Peruvian regions (2017-2019), we assessed the proportion of MRSA among S. aureus BSIs as well as the molecular typing of the isolates. A total of 166 S. aureus isolates were collected, and 36.1% of them were MRSA. Of note, MRSA isolates with phenotypic and genetic characteristics of the hospital-associated Chilean-Cordobes clone (multidrug-resistant SCCmec I, non-Panton-Valentine leukocidin [PVL] producers) were most commonly found (70%), five isolates with genetic characteristics of community-associated MRSA (CA-MRSA)-SCCmec IV, PVL-producer-(8.3%) were seen in three separate regions. These results demonstrate that hospital-associated MRSA is the most frequent MRSA found in patients with BSIs in Peru. They also show the emergence of S. aureus with genetic characteristics of CA-MRSA. Further studies are needed to evaluate the extension of CA-MRSA dissemination in Peru.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Community-Acquired Infections* / epidemiology
  • Exotoxins / genetics
  • Humans
  • Leukocidins / genetics
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Microbial Sensitivity Tests
  • Peru / epidemiology
  • Sepsis*
  • Staphylococcal Infections* / epidemiology
  • Staphylococcus aureus / genetics

Substances

  • Exotoxins
  • Leukocidins
  • Anti-Bacterial Agents